Ascendis Pharma A/S reports results for the quarter ended in December - Earnings Summary

Ascendis Pharma A/S

02/03/2022 22:23

* Ascendis Pharma A/S  ASND.OQ  reported a quarterly
adjusted loss
of €1.87​​ per share for the quarter ended in December. The mean
expectation of eleven analysts for the quarter was for a loss of
€2.34 per share.
    * Revenue rose 815.3% to €4.90 million from a year ago; 
analysts
expected €2.66 million. 
    * Ascendis Pharma A/S's reported EPS for the quarter was a
loss of
€1.87​.
    * The mean earnings estimate of analysts had fallen by
about 0.9%
in the last three months.​ 
    * In the last 30 days three analysts negatively revised
earnings
estimates 
    * Ascendis Pharma A/S shares had fallen by 19.1% this
quarter.
    * The company reported a quarterly loss of €106.06 million.
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $193.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 2 at 10:23 p.m.  ​All
figures in euros unless otherwise stated